AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 175 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 1.29 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $459,000 | +440.0% | 30,316 | +169.8% | 0.00% | – |
Q2 2022 | $85,000 | -56.6% | 11,236 | -47.8% | 0.00% | – |
Q1 2022 | $196,000 | -82.3% | 21,520 | -86.3% | 0.00% | – |
Q4 2021 | $1,106,000 | +57.1% | 157,630 | +155.7% | 0.00% | – |
Q3 2021 | $704,000 | +147.9% | 61,651 | +247.6% | 0.00% | – |
Q2 2021 | $284,000 | -66.7% | 17,737 | -62.8% | 0.00% | – |
Q1 2021 | $853,000 | -23.7% | 47,735 | -42.3% | 0.00% | -100.0% |
Q4 2020 | $1,118,000 | -27.1% | 82,731 | -36.5% | 0.00% | 0.0% |
Q3 2020 | $1,533,000 | -41.6% | 130,355 | -26.7% | 0.00% | -50.0% |
Q2 2020 | $2,627,000 | +519.6% | 177,878 | +468.8% | 0.00% | – |
Q1 2020 | $424,000 | -59.8% | 31,275 | -28.3% | 0.00% | -100.0% |
Q4 2019 | $1,055,000 | +80.7% | 43,648 | +43.8% | 0.00% | – |
Q3 2019 | $584,000 | -55.0% | 30,350 | -30.9% | 0.00% | -100.0% |
Q2 2019 | $1,298,000 | -45.0% | 43,919 | -11.6% | 0.00% | -50.0% |
Q1 2019 | $2,359,000 | -20.3% | 49,668 | -39.4% | 0.00% | 0.0% |
Q4 2018 | $2,961,000 | -52.0% | 82,006 | -18.1% | 0.00% | -60.0% |
Q3 2018 | $6,167,000 | +1757.5% | 100,175 | +1938.1% | 0.01% | – |
Q2 2018 | $332,000 | -59.3% | 4,915 | -67.4% | 0.00% | -100.0% |
Q1 2018 | $816,000 | -92.9% | 15,054 | -92.2% | 0.00% | -88.9% |
Q4 2017 | $11,539,000 | +4065.7% | 193,105 | +3281.9% | 0.01% | – |
Q3 2017 | $277,000 | +53.9% | 5,710 | +66.4% | 0.00% | – |
Q2 2017 | $180,000 | -94.1% | 3,431 | -94.9% | 0.00% | -100.0% |
Q1 2017 | $3,051,000 | +165.8% | 67,261 | +121.6% | 0.00% | +200.0% |
Q4 2016 | $1,148,000 | -91.2% | 30,346 | -91.3% | 0.00% | -92.9% |
Q3 2016 | $13,095,000 | +12253.8% | 346,965 | +5668.3% | 0.01% | – |
Q2 2016 | $106,000 | +51.4% | 6,015 | +3.4% | 0.00% | – |
Q1 2016 | $70,000 | -92.1% | 5,815 | -84.3% | 0.00% | -100.0% |
Q4 2015 | $888,000 | -71.4% | 36,982 | -79.7% | 0.00% | -75.0% |
Q3 2015 | $3,100,000 | +1980.5% | 182,286 | +1987.3% | 0.00% | – |
Q2 2015 | $149,000 | -86.0% | 8,733 | -74.5% | 0.00% | -100.0% |
Q1 2015 | $1,062,000 | +6147.1% | 34,254 | +5637.7% | 0.00% | – |
Q4 2014 | $17,000 | -82.3% | 597 | -87.6% | 0.00% | – |
Q3 2014 | $96,000 | +2300.0% | 4,809 | +2513.6% | 0.00% | – |
Q2 2014 | $4,000 | -33.3% | 184 | -39.5% | 0.00% | – |
Q1 2014 | $6,000 | +200.0% | 304 | +149.2% | 0.00% | – |
Q4 2013 | $2,000 | – | 122 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |